| Document |
Document Title |
|
JPH09508896A |
PCT No. PCT/GB95/00065 Sec. 371 Date Oct. 4, 1996 Sec. 102(e) Date Oct. 4, 1996 PCT Filed Jan. 13, 1995 PCT Pub. No. WO95/19186 PCT Pub. Date Jul. 20, 1995The present invention relates to metabolically labile esters, and to contrast medi...
|
|
JP2647882B2 |
A compound of general formula, in substantially pure form, wherein A is a cation. A method for preparation is also disclosed, together with compositions and methods of use thereof.
|
|
JPH09508351A |
The invention relates to N-alkyl peptide chelate formers, their metal complexes with radionuclides, processes for their production and radio-pharmaceutical compositions containing these compounds. The invention also relates to radio-phar...
|
|
JP2642089B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2642090B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2610674B2 |
PCT No. PCT/US88/02429 Sec. 371 Date Jan. 30, 1990 Sec. 102(e) Date Jan. 30, 1990 PCT Filed Jul. 22, 1988 PCT Pub. No. WO89/01483 PCT Pub. Date Feb. 23, 1989.The invention involves a two step chemical transformation of a steroidal 17-cya...
|
|
JP2593685B2 |
This invention is directed to 17 beta -(cyclopropyloxy)androst-5-en-3 beta -ol and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The ethers are prepared by using the Sim...
|
|
JPH09502983A |
Disclosed are 14-aminosteroid compounds, including pharmaceutically acceptable acid salts and esters thereof, useful in treating individuals afflicted with congestive heart failure, which compounds have the general formula: wherein R3 is...
|
|
JP2577771B2 |
Compounds of the general Formula (I) (I) in which R is a hydrogen atom or a bromine atom, and R1 is a hydrogen atom, an SO2OM group wherein M is a hydrogen or sodium atom, various sulphatide or phosphatide groups or a glucuronide group a...
|
|
JP2568306B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2566574B2 |
A compound of the formula: useful as cancer preventive agent, anti-obesity agent, anti-hyperglycemic agent, anti-aging agent and anti-hypercholesterolemic agent and useful in combatting coronary diseases and autoimmune diseases. Encompas...
|
|
JP2562134B2 |
Novel platinum(II)-steroid complexes are now provided, which exhibit antitumor activities as shown by tests on mouse leukemia, L-1210 cells in mice. These novel platinum(II)-steroid complexes contain a 1,2-cyclohexanediamine, a 2-(aminom...
|
|
JP2554005B2 |
PURPOSE: To extremely easily obtain estramustine phosphate having high purity with a simple operation. CONSTITUTION: Crude estramustine phosphate can be purified by dissolving the crude substance in a fatty acid ester, adding methanol (o...
|
|
JP2549721B2 |
17 beta -Cyano-17 alpha -hydroxy steroids (I) are transformed to 17 alpha -halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoid...
|
|
JP2545522B2 |
This invention provides novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of the formula: wherein R1 is beta -CH3 or beta -CH2H5; wherein R2 is H, and R3 is =0, -OH, -0-alk...
|
|
JPH08245687A |
PURPOSE: To obtain the subject new compound which is an N-substituted carbamide derivative of 3-carboxy-androst-3,5-diene and useful for treatment, etc., of acne, seborrhoica, hirsutism, alopecia, etc., as a testosterone 5α-reductase in...
|
|
JPH08225590A |
To obtain the subject new compound, a specific steroid with a 17- spiromethylene lactone group or the like, with low affinity for a progesterone receptor and slight side effects, and usable as a contraceptive, or in treating menstrual di...
|
|
JP2525049B2 |
|
|
JP2515967B2 |
PURPOSE: To obtain a new process for the preparation of corticoid and progesterone useful as pharmaceuticals by reacting a specific α-halo silyl ether with a non-nucleophilic base and then, reacting the resulting product with two specif...
|
|
JP2512439B2 |
This invention relates to novel compounds of the formula: X and Z are independently hydrogen, halogen, lower alkyl or hydroxy, or X and Z taken together are hydroxy-imino with the proviso that when Y is methyl and Z is hydrogen, X is oth...
|
|
JPH08506116A |
A use of a steroid having general formula (I), wherein R1 represents O, (H, OH), or two hydrogen atoms; R2 is hydroxy, optionally etherified or esterified; R3 is (2-6 C) alkynyl, optionally substituted with hydroxy; R4 is CN or one of th...
|
|
JP2502931B2 |
PURPOSE: To obtain a new compound useful in the treatment of hyperproliferative skin diseases such as psoriasis and sebaceous gland diseases such as seborrheic eczema. CONSTITUTION: The compound of formula I (R1 and R2 are each H or an a...
|
|
JPH08109191A |
To obtain the subject new intermediate used for synthesizing the vitamin D3 analogs, having actions for stimulating the differentiation of human keratinocytes and lowering their proliferation, and useful for treating hyperproliferative s...
|
|
JPH0899991A |
To obtain modified bile acids having linker structure useful for hypoliplemics or the like by reacting bile acid ketone with acetylenic compounds, transforming into acetylide by a strong base, followed catalytic hydrogenation by Pd/C. Th...
|
|
JPH0826062B2 |
9-Alpha-hydroxy- steroids (I) contg. a D-ring of formula (A) are new; R2 = ethynyl (provided R5 is not acetoxy if R4 = H), haloethynyl, opt. protected OH, cyano, 1'-Ra-ethenyl; or 1',1'-trimethylene dithio-ethyl; Ra = 1-6C alkoxy or alky...
|
|
JPH0827179A |
PURPOSE: To commercially obtain sodium salt of estramustine phosphate having high purity capable of being used as medicines without using a specific catalyst and solvent. CONSTITUTION: This method for producing sodium salt of estramustin...
|
|
JPH085910B2 |
Process for the production of a DELTA <17(20)>-steroid of formula (II) which comprises starting with a 16-unsaturated corticoid of formula (I) and contacting the 16-unsaturated corticoid (I) with a methylating agent in the presence of a ...
|
|
JPH07316186A |
PURPOSE: To obtain a novel nor-bile derivative obtained by bonding plural bile acid groups, having high affinity with a bile acid-transporting system of intestine, capable of inhibiting bile acid absorption and useful as antihyperlipidem...
|
|
JPH0794377B2 |
An injectable pharmaceutical formulation for use in cancer treatment comprises 3-benzoyloxy-1,3,5(10)-estratriene-17-[4-{p-(bis(2-chloroeth
yl)amino)- phenyl}-HY # butanoyloxy]acetate dissolved in an ester of iodinated poppy oil fatty ac...
|
|
JPH0772193B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JPH07506372A |
Abnormally elevated levels of IL-6 are associated with a number of pathologic disorders. Compositions comprised of DHEA congeners are useful for the treatment of an individual to reduce an abnormally eleveted IL-6 level.
|
|
JPH0755960B2 |
New processes for preparing new steroid derivatives including ergosta-1,5,7,22-tetraen-3 beta -ol, 1 alpha -hydroxy-ergosteryl diacetate, etc. which are useful intermediates in the synthesis of 1 alpha -hydroxy vitamin D2. The processes ...
|
|
JPH0755959B2 |
17 alpha -bromo- alpha and 17 alpha -iodo-vinyl-estrane derivatives of general formula I (I) wherein X is a bromine or iodine atom in Z or E position, R1 is hydrogen, hydroxy or acyloxy with up to 3 C atoms, R2 is hydrogen, alkyl with up...
|
|
JPH07504900A |
Viral infection is inhibited in mammals by administration of metabolically stable, non-toxic 2',5'-oligoadenylate (2-5A) derivatives that have a dual therapeutic effect. The compounds activate the intracellular latent 2-5A dependent endo...
|
|
JPH0745511B2 |
Compounds of formula (I) : in which, inter alia, R<1> is H or C1-8alkyl and M is O or S, processes for their preparation, pharmaceutical compositions containing then and their use as inhibitors of 5- alpha -reductase in the treatment in ...
|
|
JPH0742306B2 |
This invention provides a new method for preparing 26,26,26,27,27,27-hexafluoro-1,25-dihydroxycholesterol. The method permits the use of cholenic acid or an ester of cholenic acid as the starting material and the preparation of a compoun...
|
|
JPH0742305B2 |
This invention provides a new method for preparing 26,26,26,27,27,27-hexafluoro-1,25-dihydroxycholesterol. The method permits the use of cholenic acid or an ester of cholenic acid as the starting material and the preparation of a compoun...
|
|
JPH07503708A |
Novel glycosylated steroid derivatives for facilitating the transport of compounds across biological membranes are disclosed. A novel process for efficient synthesis of these glycosylated steroid derivatives, using activated glycosyl sul...
|
|
JPH0735395B2 |
Described are new agents for treating bone disorders associated with a reduction in bone mass and abnormalities in bone resorption or bone formation including osteoporosis, Paget's disease, bone metastases and malignant hypercalcemia. Th...
|
|
JPH07503466A |
PCT No. PCT/US93/00211 Sec. 371 Date Jul. 25, 1994 Sec. 102(e) Date Jul. 25, 1994 PCT Filed Jan. 26, 1993 PCT Pub. No. WO93/15103 PCT Pub. Date Aug. 5, 1993.Novel steroids having a 9 alpha -hydroxy or a 9 alpha -carbonate substituent can...
|
|
JPH0730109B2 |
DELTA <4>-3-keto, DELTA <1,4>-3-keto and 3 beta -hydroxy-17-keto-steroids are transformed into the corresponding 16 beta -methyl-17-keto-steroids by activating the C-16 position, metylating, and reacting with a strong base. The C-3 posit...
|
|
JPH07503008A |
Invented is an improved process for the preparation of benzo esters and benzo acids. Also invented are novel intermediates used in said process.
|
|
JPH0725791B2 |
A process for dehydrogenating a compound of the formula which comprises reacting the compound with a silylating agent in the presence of a quinone to introduce a DELTA <1> double bond. Novel intermediates are compounds of the formula whe...
|
|
JPH0720938B2 |
This invention relates to a selective acylation process for the preparation of phenolic N-disubstituted carbamate esters of steroids, comprising reacting in an inert solvent an acylating agent being a carbamoyl halogenide, a 4-(tertiary ...
|
|
JPH07500119A |
This invention refers to compounds of formula (I) or double bonds; R is hydrogen or C1-C4 alkyl; R1 is hydrogen or an acyl group; R2 is hydrogen; C1-C4 alkyl unsubstituted or substituted by phenyl; phenyl unsubstituted or substituted by ...
|
|
JPH06510982A |
Compounds are provided which are highly selective inhibitors of the cytochrome P-450C17, commonly known as 17,20-lyase enzyme, responsible for androgen biosynthesis. These compounds can be administered to patients to inhibit the producti...
|
|
JPH0699470B2 |
The invention relates to a new process for the preparation of 21-hydroxy-20-keto-steroids from 17-(isocyano-sulfonylmethylene)-steroids whereby simultaneously an unsaturated bond is introduced between C16 and C17. Furthermore the inventi...
|
|
JPH06329697A |
PURPOSE: To provide a medicine for improvement of bone diseases, containing a bisphosphonated steroid hormone, etc., as the active component, free from decomposition in blood, exhibiting its pharmaceutical activity by selective adsorptio...
|
|
JPH06510020A |
The invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein [D] is the residue of a drug having a reactive functional group, said functional group being attached, directly or through a bridg...
|
|
JPH06211893A |
PURPOSE: To provide the novel derivative exhibiting low toxicity and useful for remedy for diseases such as hear failure, hypertension or the like containing the derivative active on cardiovascular system. CONSTITUTION: By condensing a 1...
|
